NCT05171075终止3 期
A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab vs. Dalteparin on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients With GI/GU Associated VTE
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 417
- 试验地点
- 229
- 主要终点
- Time to first event of centrally adjudicated VTE recurrence
研究概览
简要总结
This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE (Magnolia)
详细描述
Cancer associated thrombosis (CAT) is a severe medical condition which is characterized by high incidence of Venous thromboembolism (VTE) recurrence and high risk for bleeding. Patients with intact GI and GU cancer have increased bleeding risk with oral direct anticoagulants (DOACs), Guidelines advice caution with those DOACs or state preference for low molecular weight heparin (LMWH) in this population. The ANT-008 study will compare treatment with abelacimab monthly administration to LMWH daily subcutaneous (sc) administration over 6-month treatment. The study outcomes include VTE recurrence, bleeding event and treatment discontinuation at 6 months
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female subjects ≥18 years old or other legal maturity age according to the country of residence
- •Confirmed GI (colorectal, pancreatic, gastric, esophageal, gastro-esophageal junction or hepatobiliary) or confirmed GU (renal, ureteral, bladder, prostate, or urethra) cancers if:
- •Unresectable, locally advanced, metastatic, or non-metastatic GI/GU cancer and
- •No intended curative surgery during the study
- •Confirmed symptomatic or incidental proximal lower limb deep vein thrombosis (DVT) (i.e., popliteal, femoral, iliac, and/or inferior vena cava vein thrombosis) and/or a confirmed symptomatic pulmonary embolism (PE), or an incidental PE in a segmental, or larger pulmonary artery. Patients are eligible within 120 hours from diagnosis of the qualifying VTE.
- •Anticoagulation therapy with LMWH for at least 6 months is indicated
- •Able to provide written informed consent
排除标准
- •Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current (index) occurrence of DVT and/or PE
- •More than 120 hours of pre-treatment with therapeutic doses of UFH, LMWH, or other anticoagulants
- •An indication to continue treatment with therapeutic doses of an anticoagulant other than for VTE treatment prior to randomization (e.g., atrial fibrillation, mechanical heart valve, prior VTE)
- •PE leading to hemodynamic instability (systolic BP <90 mmHg or shock).
- •Acute ischemic or hemorrhagic stroke or intracranial hemorrhage, in the last 4 weeks preceding screening.
- •Brain trauma, or cerebral or a spinal cord surgery or spinal procedures such as lumbar puncture or epidural/spinal anesthesia within 4 weeks of screening
- •Need for aspirin in a dosage of more than 100 mg/day or, any other antiplatelet agent alone or in combination with aspirin
- •Bleeding requiring medical attention at the time of randomization or in the preceding 4 weeks
- •Planned brain, spinal cord, cardiac, vascular, major thoracic and/or major abdominal surgery in the 4 weeks following randomization
- •History of heparin induced thrombocytopenia
- •Infective acute or subacute endocarditis at the time of presentation
- •Primary brain cancer or untreated intracranial metastasis
- •Eastern Cooperative Oncology Group (ECOG) performance status of 3 or 4 at screening
- •Life expectancy of <3 months at randomization
- •Calculated creatinine clearance (CrCl) <30 mL/min at the screening visit
- •Platelet count <50,000/ mm3 at the screening visit
- •Hemoglobin <8 g/dL at the screening visit
- •Acute hepatitis, chronic active hepatitis, liver cirrhosis; or an alanine aminotransferase ≥3 times and/or bilirubin ≥2 times the upper limit of normal (ULN) at the screening visit in the absence of clinical explanation
- •Uncontrolled hypertension (systolic blood pressure [BP] > 180 mm Hg or diastolic BP >100 mm Hg despite antihypertensive treatment)
- •Women of child-bearing potential (WOCBP) who are unwilling or unable to use highly effective contraceptive measures during the study from screening up to 3 days after last treatment of dalteparin or 100 days after administration of abelacimab
- •Sexually active males with sexual partners of childbearing potential must agree to use a condom or other reliable contraceptive measure up to 3 days after last treatment of dalteparin or 100 days after administration of abelacimab
- •Pregnant or breast-feeding women
- •History of hypersensitivity to any of the study drugs (including dalteparin) or its excipients, to drugs of similar chemical classes, or any contraindication listed in the label for dalteparin
- •Subjects with any condition that in the judgement of the Investigator would place the subject at increased risk of harm if he/she participated in the study
- •Use of other investigational (not-registered) drugs within 5 half-lives prior to enrollment or until the expected pharmacodynamic effect has returned to baseline, whichever is longer. Participation in academic non-interventional studies or interventional studies, comprising testing different strategies or different combinations of registered drugs is permitted.
研究组 & 干预措施
Abelacimab
Experimental
Abelacimab intravenous administration followed by monthly administration of the same dose subcutaneously
干预措施: Abelacimab (Biological)
Dalteparin
Active Comparator
Dalteparin administered subcutaneously daily
干预措施: Dalteparin (Drug)
结局指标
主要结局
Time to first event of centrally adjudicated VTE recurrence
时间窗: up to 6 months
Time to first adjudicated venous thromboembolism (VTE) event recurrence
次要结局
- Time to first event of ISTH-adjudicated major or clinically relevant non-major (CRNM) bleeding events(up to 6 months)
- Time to first event of VTE recurrence, ISTH adjudicated major or ISTH-adjudicated CRNM bleeding events(up to 6 months)
- Time to event of permanent treatment discontinuation not due to death(up to 6 months)
- Time to first event of ISTH-adjudicated CRNM bleeding events(up to 6 months)
- Time to first event of ISTH-adjudicated major bleeding events(Up to 6 months)
- Time to first event of GI ISTH-adjudicated major and GI CRNM bleeding events(up to 6 months)
- All-cause death, vascular death, serious adverse events, adverse events leading to drug discontinuation, other adverse events, abnormal lab tests, etc. presented as rate per 100 patient-years(up to 6 months)
- For patients treated with abelacimab: percent with injection site reactions/severity, hypersensitivity reactions/severity, anti-drug antibody formation, neutralizing antibody(up to 6 months)
研究者
研究点 (229)
Loading locations...
相似试验
终止
3 期
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTEDeep Venous ThrombosisPulmonary EmbolismVenous ThromboembolismNCT05171049Anthos Therapeutics, Inc.1,150
终止
3 期
Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the BladderCarcinoma in SituTransitional Cell CarcinomaNon-muscle Invasive Bladder CancerNCT01310803Endo Pharmaceuticals1
已完成
3 期
A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing ChemotherapyCarcinoma, Non-Small-Cell LungNCT02813785Hoffmann-La Roche565
已完成
3 期
A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor TreatmentCarcinoma, Renal CellNCT04338269Hoffmann-La Roche522
终止
3 期
A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS)Myelodysplastic Syndromes(MDS)NCT05709093TJ Biopharma Co., Ltd.10